Skip to main content

AS/Spondyloarthritis

    The last day was jammed with important reports and research including the late breaking abstracts.    What imaging modality is best in GCA? Dutch study: n=42 ?GCA got all three of USS, PET/CT, MRI…
    A few things we know about opioids: use is common; it’s not efficacious in the treatment of spondyloarthritis; and, there is an opioid epidemic and its users are stigmatized.  Opioid use can weigh…
    Chronic back pain is one of the most common symptoms encountered in the outpatient setting. It affects a significant portion of the population, resulting in greater use of healthcare resources. The…
    A new target for treatment in AxSpA is the dual inhibition of IL17A and IL17F (IL17A/F). IL17A is a key driver of the inflammation in the AxSpA and Psoriatic Arthritis (PsA). IL17A and its…
    Vaccine efficacy remains an important and highly discussed topic at this year’s annual meeting given the ongoing COVID-19 global health crisis, current influenza season, and recently published 2022…
    Day two at ACR 2022 was full of great sessions on imaging, vasculitis, lupus, vasculitis, spondyloarthritis, COVID, pregnancy, microbiome, economics and more. Here are the RheumNow faculty…
    Many practicing, and retired, rheumatologists will recall a time when we only had TNFi for the treatment of SpA. These drugs changed the landscape of disease and for the first time, we felt we had…
    The RheumNow faculty reporters have been scouring the meeting and online presentations to find the best abstracts from ACR22. Here are some of their choice abstracts reported today on day 1 of ACR…
    There have been big advances in the treatment of axial spondyloarthritis (AxSpA) in the last decade. Biologic drugs that target TNF and IL-17 have become mainstay treatments in AxSpA if the disease…
    When it comes to Spondyloarthritis we have numerous disease activity measures and much debate regarding best practices. When it comes to determining which to use in clinic, discrepancies occur. Do…